Circular 36/2015/tt-Byt: Amendments And Supplements To Some Articles Of The Circular 40/2014/tt-Byt On 17Th November 2014 And The Guide Made The Category Medicine Payment Range Of Qu

Original Language Title: Thông tư 36/2015/TT-BYT: Sửa đổi, bổ sung một số điều của Thông tư số 40/2014/TT-BYT ngày 17 tháng 11 năm 2014 ban hành và hướng dẫn thực hiện danh mục thuốc tân dược thuộc phạm vi thanh toán của qu

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$20 per month, or Get a Day Pass for only USD$4.99.
MINISTRY OF HEALTH
Number: 36 /2015/TT-BYT
THE SOCIALIST REPUBLIC OF VIETNAM.
Independence-Freedom-Happiness
Hanoi, October 29, 2015

IT ' S SMART

Modify, add some of the I Number of hips 40 /2014/TT-BYT

November 17, 2014 issued and guided the implementation of the new drug portfolio.

of the payment range of the health insurance fund

_____________________

Law Base Bitch. Medical emergency;

Base of Decree Stain. 63 /2012/NĐ-CP August 31, 2012 by Ch I'm Ph. brew Function, mission, rule. Okay. Limit and structure socket function of the Ministry of Health;

Base of Decree One. 05 /2014/ND-CP 15 1 A 2014 Government of the Government y I'm i And then. There. n execs a Stain. Article brew a health insurance law;

Repository in The Ministry of Health has issued a revision of the Ministry of Commerce, which adds up to a Stain. The article of the Stain. 40/20 1 4/TT-BYT November 17 n What? 2014 issued and guided the implementation of a new drug-payment category. brew A secure fund. Okay. Medical.

What? 1. Modified, supplement some of the provisions of the Digital 40 /2014/TT-BYT November 17, 2014:

1. Catalogue of the drug drug issued by Digital Information 40 /2014/TT-BYT November 17, 2014 is revised, adding a number of points as follows:

a) "Anti-human thymocyte immunoglobulin" (number 340, column 2) to "Anti thymocyte globulin";

b) The correct name "Hydroxycarbamide" (370, column 2) to "Hydroxycarbamide/Hydroxyurea";

c) The correct name "methoxy polyethylene glycol epoietin beta" (order 474, column 2) to "Methoxy polyethylene glycol epoetin beta";

d) The correct name "S-bioballthrin + piperonylbuttoxid" (serial number 605, column 2) to "S-bioallethrin + piperonyl butoxid";

"Attapulgit mormoivon activates + mixture magnesi carbonat-aluminium hydroxyd" (order 663, column 2) to "Attapulgit mormoiron activates + mixer magnesi carbonat-aluminium hydroxyd";

e) "Acid thioctic; Meglumin thioctat" (order 940, column 2) to "Acid thioctic/Meglumin thioctat";

g) Modifies the sentence "Health Insurance Fund for stroke treatment, post-traumatic brain injury and surgery and post-brain neurosurgery" (Column 9 of the Peptid drug (Cerebrolysin concentrate), number 561, column 2; Choline alfoscerat, number of order 562, column 2 and drug Citicolin, serial number 563, column 2) to "The Health Insurance Fund for Acute Stroke Treatment, following trauma and brain injury and post-brain neurosurgery";

h) Amendment to the "Health Insurance Fund for treatment of pain treatment caused by vasculitis (pain of travel); visual disorder (retinal disease); sensory neurotic disorder caused by local anemia; Raynaud syndrome" (Column 9 of the drug Ginkgo biloba, the order) 566, column 2) to " The Health Insurance Fund that protects the pain of vasculitis (pain in the go); visual disorders (retinal disease of diabetes); throat ears (dizziness, ear, hearing loss), sensory neurological circulation disorder due to lack of local blood; Raynaud syndrome ";

i) Modification of the sentence "The treatment for the health insurance payment of increased blood ammonia and brain disease, liver disease when there is a clear sign of disease, cancer patients have specified chemical treatment or prehistory of hepatitis" (column 9 of the drug L-Ornithin-L-aspartat, the order) 747, column 2) to "The Health Insurance Fund that increases blood ammonia in liver disease when there is a clear sign of disease; cancer patients have indications of chemical treatment; cancer patients have a history of hepatitis";

K) amended the sentence of " The Health Insurance Fund for Immunodeficiency Treatment for Free Diabetes, Guillain Barre syndrome, Kawasaki disease; alternative treatment for IgG deficiency patients, treatment of hand-footed disease in the direction of diagnosis and treatment of the Ministry of Health; treatment of severe infections "(column 9 of Immune globulin, order 821, column 2) to" The Health Insurance Fund for Immunodeficiency Therapy, Guillain Barre syndrome, Kawasaki disease; alternative treatment for IgG deficiency patients, treatment of patients. " Hand-to-mouth disease in the direction of diagnosis and treatment of the Ministry of Health; treatment of severe infections ";

l) Modifies the sentence "Payment Health Insurance Fund: Ringer acetate; Ringer acetate; Ringerfundin" (column 9 of Ringer lactat, number 1026, column 2) to "Payment Health Insurance Fund: Ringer lactat; Ringer acetate; Ringerfundin";

m) Limited designation, hospital class limits on sodium + cholecalciferol (Vitamin D3), drink (order number 66, column 2): Health insurance fund treating osteoporosis, use at special class hospital osteoporosis and specialty. Class I;

n) Type of drug Gatifloxacin, small form (order number 863, column 2) out of the issued drug category accompanied by Digital Information 40 /2014/TT-BYT November 17, 2014.

2. Add paragraph 4 Article 5 as follows:

" 4.

What?

The case of a combination of drugs in which there is a limiting condition, the only payment is that the payment is limited to the condition of the condition, which indicates the payment.

The case of a combination of compounds in which there are two conditions that limit the conditions, specify the return payment, and apply at the same time the conditions limit, specify the payment ".

3. Modified, add 1, paragraph 2 Article 7 as follows:

a) Add to 1 Article 7 as follows:

" 1.

What?

For patients with cancer are using 4 Pegylated liposomal Doxorubicin, injectable form; Erlotinib medication, drink form; Gefitinib, oral form; Sorafenib medication, oral form at the clinic, healing before the Digital Day. 40 /2014/TT-BYT November 17, 2014 comes into effect and the following July 1, 2015, continues to be paid by the health insurance fund 100% of the prescribed cost at the U.S. Digital Information. 31 /2011/TT-BYT July 11, 2011 in the following cases:

-Use until the course of treatment (from the time when the patient is diagnosed with the diagnosis, begin treatment to the end of treatment).

-The case after treatment at the clinic, curing the disease, the person who moved to the clinic, treated the other, was designated by the doctor, but still in therapy, the health insurance fund continued to pay 100% of the cost. The range of rights is regulated by regulation (except for the case of foreign outpatient treatment).

-The case of patients who use the medication has a side effect or the basis of the disease, cure the disease, the doctor only moves to another drug (the conversion from Erlotinib, the drink to Gefitinib, the form of drink, and vice versa).

-Patient treatment is suspended and stopping treatment, when recurred, the doctor only uses treatment for treatment.

-During the treatment of one of these four drugs, the patient did not come to the correct examination, the treatment was not constant. ";

b) Modip 2 Article 7 as follows:

" 2. For the medicines within the payment range of the health insurance fund by regulation at the Digital Information. 31 /2011/TT-BYT July 11, 2011, Digital News 10 /2012/TT-BYT June 8, 2012 amendment, adds some of the provisions of the Digital Information 31 /2011/TT-BYT on July 11, 2011 and the cancer drugs, anti-discharge drugs in addition to the prescribed drug portfolio at Clause 4 Article 7 of the number of 09 /2009/TTLT-BYT-BTC On August 14, 2009, the health insurance fund continued to pay until the end of the number of drugs that had been contracted according to the results of the drug supply bid and was given the basis of the disease, treating the contract to contract with the contractor prior to 1 January 2015.

For the medicines within the payment range of the health insurance fund by regulation at the Digital Information. 31 /2011/TT-BYT July 11, 2011, Digital News 10 /2012/TT-BYT June 8, 2012 amendment, adds some of the provisions of the Digital Information 31 /2011/TT-BYT on July 11, 2011 and the cancer drugs, anti-discharge drugs in addition to the prescribed drug portfolio at Clause 4 Article 7 of the number of 09 /2009/TTLT-BYT-BTC August 14, 2009, which moved to Digital News 40 /2014/TT-BYT November 17, 2014 but is limited to the use of the hospital class, the health insurance fund continues to pay under the prescribed hospital class at No. 1. 31 /2011/TT-BYT July 11, 2011, Digital News 10 /2012/TT-BYT June 8, 2012 amendment, adds some of the provisions of the Digital Information 31 /2011/TT-BYT July 11, 2011 and Digital Federal Information 09 /2009/TTLT-BYT-BTC August 14, 2009 until the expiration of the number of drugs that had been registered as a result of the drug supply bid and was given the basis of a medical examination, treatment for contracting the contract was provided to the contractor prior to 1 January 2015.

For the medications Lysin hydrochlorid + Calcium glycerophosphate + Acid glycerophosphoric + Vitamin B1 + B2 + B6 + E + PP, drinking (order 1116, column 2); Iron sulfate + lysin hydrochlorid + vitamin A + B1 + B2 + B3 + B6 + B12 + D + calci glycerophosphate + magnesi gluconat, drink (order 1118, column 2) and vitamin A + B1 + B2 + B6 + C + D3 + calci gluconat + zinc + lysin + PP, drink (order 1135, column 2) at Digital News 31 /2011/TT-BYT July 11, 2011, the health insurance fund continues to pay its use for all ages of adults and children, the hospital class according to the provisions of the Digital Information. 31 /2011/TT-BYT July 11, 2011, until the end of the number of drugs that had been contracted by the result of the bid for the medication and was given the basis of the medical examination, the treatment of the contract was provided to the contractor prior to 1 January 2015.

For Lysin hydrochlorid + Calci glycerophosphate + Acid glycerophosphoric + Vitamin B1 + B2 + B6 + E + PP, drinking (number order 1116, column 2) 31 /2011/TT-BYT July 11, 2011: As Lysin + Vitamin + Minerals, Drink (order 1042, Column 2) Digital. 40 /2014/TT-BYT November 17, 2014, the health insurance payment payment fund treatment for children under 6 years of malnutrition, used for special class hospitals, Class I and Class II according to the provisions of the U.S. Digital Information. 40 /2014/TT-BYT November 17, 2014 according to the results of the contract for the drug supply and has been given the basis of a medical examination, treatment for contracting the contract was provided to the contractor from 1 January 2015.

What? 2. Hi Don't I Well, c

It has been in effect since December 15, 2015.

In the course of the organization, if there is a difficulty in the request for the Ministry of Health to review the Ministry of Health (Health Insurance) to review, resolve the ./

KT. MINISTER.
Chief.

(signed)

Nguyen Thi